April 23rd 2025
The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone
September 25th 2023The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.
Adaptive Biotechnologies Announces Collaboration with Takeda for Minimal Residual Disease Measures
April 28th 2023clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.
AMB-05X Receives EMA PRIME Designation for Treatment of Tenosynovial Giant Cell Tumor
January 20th 2023The efficacy data across multiple clinical endpoints and a favorable safety profile support the potential of AMB-05X as a best-in-class therapy for the treatment of TGCT regardless of surgical resectability.
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.